Post-triptan era for the treatment of acute migraine.
There now is one realized and several attractive targets for the treatment of acute attacks of migraine that will follow and augment the use of serotonin 5-HT1B/1D receptor agonists, the triptans. Calcitonin gene-related peptide (CGRP) receptor blockade recently has been shown to be an effective acute antimigraine strategy; therefore, blockade of CGRP release by inhibition of trigeminal nerves would seem a logical approach. A number of targets are reviewed in this article including serotonin 5-HT1F and 5-HT1D receptors, adenosine A1 receptors, nociceptin, vanilloid TRPV1 receptors, and anandamide CB1 receptors. Development of one or more such compound offers the exciting prospect of new non-vasoconstrictor treatments for migraine and cluster headache.
Goadsby
Peter J
PJ
Institute of Neurology, Queen Square, London WC1N 3BG, UK. peterg@ion.ucl.ac.uk
D000208:Acute Disease; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D002211:Capsaicin / Q000494:pharmacology* / Q000627:therapeutic use*; D003027:Cluster Headache / Q000188:drug therapy; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D018847:Opioid Peptides / Q000494:pharmacology* / Q000627:therapeutic use*; D043682:Receptor, Adenosine A1 / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology* / Q000627:therapeutic use*; D014276:Trigeminal Nerve / Q000187:drug effects*; D014364:Tryptophan / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000097629:Nociceptin
D018687:Antidepressive Agents, Second-Generation; D002211:Capsaicin; D018847:Opioid Peptides; D043682:Receptor, Adenosine A1; D017366:Serotonin Receptor Agonists; D014364:Tryptophan; D014665:Vasodilator Agents; D000097629:Nociceptin